Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
LPCN 1002 is a branded product for female hormonal disorders currently in Phase I studies specifically targeting Endometrial hyperplasia and secondary amenorrhea. More